KR101796689B1 - 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 - Google Patents
안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 Download PDFInfo
- Publication number
- KR101796689B1 KR101796689B1 KR1020167015418A KR20167015418A KR101796689B1 KR 101796689 B1 KR101796689 B1 KR 101796689B1 KR 1020167015418 A KR1020167015418 A KR 1020167015418A KR 20167015418 A KR20167015418 A KR 20167015418A KR 101796689 B1 KR101796689 B1 KR 101796689B1
- Authority
- KR
- South Korea
- Prior art keywords
- ser
- leu
- gly
- val
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2012/006680 WO2014030780A1 (en) | 2012-08-22 | 2012-08-22 | Screening and engineering method of super-stable immunoglobulin variable domains and their uses |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157004214A Division KR101732552B1 (ko) | 2012-08-22 | 2012-08-22 | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160072272A KR20160072272A (ko) | 2016-06-22 |
| KR101796689B1 true KR101796689B1 (ko) | 2017-11-10 |
Family
ID=50150075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167015418A Active KR101796689B1 (ko) | 2012-08-22 | 2012-08-22 | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 |
| KR1020157004214A Active KR101732552B1 (ko) | 2012-08-22 | 2012-08-22 | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157004214A Active KR101732552B1 (ko) | 2012-08-22 | 2012-08-22 | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10078085B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2888367B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6073038B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR101796689B1 (cg-RX-API-DMAC7.html) |
| CN (3) | CN113234142B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014030780A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113234142B (zh) * | 2012-08-22 | 2024-03-05 | 财团法人牧岩生命工学研究所 | 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| GB201419899D0 (en) | 2014-11-07 | 2014-12-24 | Univ Kent Canterbury | Biopharmaceutical production method |
| MX2017006167A (es) | 2014-11-12 | 2018-03-23 | Siamab Therapeutics Inc | Compuestos que interactúan con glicanos y métodos de uso. |
| KR101692629B1 (ko) * | 2015-07-14 | 2017-01-03 | 계명대학교 산학협력단 | 매시브 플래카드 제어 장치 및 그 방법 |
| CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| EP3452516A4 (en) * | 2016-05-04 | 2019-11-27 | Abilita Bio, Inc. | Methods and platform for preparing multispanning membrane proteins |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| KR20240044544A (ko) | 2017-03-03 | 2024-04-04 | 씨젠 인크. | 글리칸-상호작용 화합물 및 사용 방법 |
| EP3459968A1 (en) * | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| WO2019066435A2 (ko) * | 2017-09-29 | 2019-04-04 | 재단법인 목암생명과학연구소 | Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| KR102115300B1 (ko) | 2018-06-01 | 2020-05-26 | 재단법인 목암생명과학연구소 | 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법 |
| CN108893487A (zh) * | 2018-07-19 | 2018-11-27 | 中国农业科学院北京畜牧兽医研究所 | 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法 |
| AU2019408420B2 (en) * | 2018-12-21 | 2025-04-17 | Vib Vzw | Fusion protein with a toxin and scaffold protein |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016591A2 (en) * | 2005-08-01 | 2007-02-08 | Cornell Research Foundation, Inc. | Compositions and methods for monitoring and altering protein folding and solubility |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960007784B1 (ko) | 1993-07-02 | 1996-06-12 | 포항종합제철 주식회사 | 일산화탄소(co)가스 센서 및 그 제조방법 |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| EP1137664A2 (en) * | 1998-12-10 | 2001-10-04 | Washington University | Protein transduction system and methods of use thereof |
| EP1214352A2 (en) | 1999-09-07 | 2002-06-19 | Viventia Biotech Inc. | Enhanced phage display libraries of human vh fragments and methods for producing same |
| ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
| JP2005289809A (ja) * | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| CN102093477B (zh) * | 2002-05-22 | 2014-02-26 | 艾斯巴技术-诺华有限责任公司 | 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法 |
| NZ540194A (en) * | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| GB0226729D0 (en) | 2002-11-15 | 2002-12-24 | Medical Res Council | Intracellular antibodies |
| EP1644416A4 (en) | 2003-06-30 | 2007-08-29 | Centocor Inc | ANTI-TARGET AND GENETICALLY MODIFIED IMMUNOGLOBULIN-DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
| UA89481C2 (uk) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| EP1786463A4 (en) * | 2004-03-26 | 2009-05-20 | Human Genome Sciences Inc | ANTIBODY AGAINST NOGO RECEPTOR |
| ES2377979T3 (es) * | 2004-09-03 | 2012-04-03 | Genentech, Inc. | Antagonistas anti-beta7 humanizados y utilizaciones para los mismos |
| US9150850B2 (en) | 2005-08-22 | 2015-10-06 | Cornell Research Foundation, Inc. | Compositions and methods for analyzing protein interactions |
| BRPI0710572A2 (pt) | 2006-01-24 | 2013-01-08 | Domantis Limited | ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas |
| KR100981356B1 (ko) * | 2006-01-31 | 2010-09-14 | 대한민국 | 신호서열 및 변이된 신호서열로 디자인된 분비증강자에의한 원래 형태의 수용성 재조합 단백질 생산 방법 |
| EP2016101A2 (en) | 2006-05-09 | 2009-01-21 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
| WO2008112640A2 (en) * | 2007-03-09 | 2008-09-18 | Sinomab Bioscience Limited | Construction and use of a functionally human antibody library with maximized repertoire diversity |
| CA2691109A1 (en) | 2007-06-18 | 2008-12-24 | Kai Bao | Tat signal peptides for producing proteins in prokaryotes |
| EP2238165B1 (en) | 2008-01-07 | 2017-07-05 | Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Anti-hiv domain antibodies and method of making and using same |
| RU2013139260A (ru) * | 2011-01-28 | 2015-03-10 | Нэшнл Рисеч Каунсил Оф Канада | Конструирование иммуноглобулиновых доменов |
| CN113234142B (zh) * | 2012-08-22 | 2024-03-05 | 财团法人牧岩生命工学研究所 | 超稳定免疫球蛋白可变结构域的筛选和改造方法及其应用 |
-
2012
- 2012-08-22 CN CN202110418890.8A patent/CN113234142B/zh active Active
- 2012-08-22 US US14/422,912 patent/US10078085B2/en active Active
- 2012-08-22 KR KR1020167015418A patent/KR101796689B1/ko active Active
- 2012-08-22 EP EP12883278.9A patent/EP2888367B1/en active Active
- 2012-08-22 KR KR1020157004214A patent/KR101732552B1/ko active Active
- 2012-08-22 WO PCT/KR2012/006680 patent/WO2014030780A1/en not_active Ceased
- 2012-08-22 CN CN201280076586.9A patent/CN104769113B/zh active Active
- 2012-08-22 CN CN201610833668.3A patent/CN106986934B/zh active Active
- 2012-08-22 JP JP2015528372A patent/JP6073038B2/ja active Active
- 2012-08-22 EP EP16202979.7A patent/EP3165535B1/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007016591A2 (en) * | 2005-08-01 | 2007-02-08 | Cornell Research Foundation, Inc. | Compositions and methods for monitoring and altering protein folding and solubility |
Non-Patent Citations (2)
| Title |
|---|
| Annu Rev Microbiol. 2006;60:373-95 |
| Protein Expr Purif. 2012 Jul;84(1):167-72 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3165535A1 (en) | 2017-05-10 |
| US10078085B2 (en) | 2018-09-18 |
| US20160003844A1 (en) | 2016-01-07 |
| EP3165535B1 (en) | 2019-05-15 |
| JP2015531597A (ja) | 2015-11-05 |
| CN104769113A (zh) | 2015-07-08 |
| JP6073038B2 (ja) | 2017-02-01 |
| KR20150032337A (ko) | 2015-03-25 |
| KR101732552B1 (ko) | 2017-05-08 |
| CN104769113B (zh) | 2017-10-31 |
| CN113234142A (zh) | 2021-08-10 |
| CN106986934A (zh) | 2017-07-28 |
| EP2888367A1 (en) | 2015-07-01 |
| EP2888367A4 (en) | 2016-04-20 |
| CN106986934B (zh) | 2021-09-14 |
| CN113234142B (zh) | 2024-03-05 |
| WO2014030780A1 (en) | 2014-02-27 |
| KR20160072272A (ko) | 2016-06-22 |
| EP2888367B1 (en) | 2020-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101732552B1 (ko) | 안정화된 면역글로불린가변도메인 선별방법 및 선별된 도메인의 응용 | |
| JP2015531597A5 (cg-RX-API-DMAC7.html) | ||
| US10633430B2 (en) | Engineering of immunoglobulin domains | |
| JP6253986B2 (ja) | コレクション及びその使用方法 | |
| US9102711B2 (en) | Methods and materials for targeted mutagenesis | |
| US20180319869A1 (en) | Method for mass humanization of rabbit antibodies | |
| CN105247050B (zh) | 用于文库构建、亲和力结合剂筛选和其表达的整合系统 | |
| US20190085323A1 (en) | Phage-displayed single-chain variable fragment libraries and uses thereof | |
| CN110003336B (zh) | Pd-1单域抗体、核苷酸序列及试剂盒 | |
| KR102216032B1 (ko) | 합성 항체 라이브러리의 생성 방법, 상기 라이브러리 및 그 적용(들) | |
| JP6293829B2 (ja) | 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用 | |
| HK40051447A (en) | Screening and engineering method of super-stable immunoglobulin variable domains and their uses | |
| HK40051447B (en) | Screening and engineering method of super-stable immunoglobulin variable domains and their uses | |
| US12024796B2 (en) | Variable heavy chain only libraries, methods of preparation thereof, and uses thereof | |
| CN113651889B (zh) | 一种抗EphA2全人源双价重组抗体scFv-Fc | |
| EP3209699A1 (en) | Vh scaffold | |
| Huhtinen | Advancing antibody engineering: Development of a novel Bxb1 landing pad-based mammalian display platform for the selection of biophysically favorable antibodies | |
| Salema et al. | Advances in Antibody Phage Display-A review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A18-div-PA0104 St.27 status event code: A-0-1-A10-A16-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| FPAY | Annual fee payment |
Payment date: 20201021 Year of fee payment: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20211021 Year of fee payment: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20220916 Year of fee payment: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| S14-X000 | Exclusive voluntary license recorded |
St.27 status event code: A-4-4-S10-S14-lic-X000 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 8 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 9 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 9 |